Cargando…
Clinical trial design in phase 2 and 3 trials for pulmonary hypertension
This article on clinical trial design incorporates the broad experience of members of the Pulmonary Vascular Research Institute’s (PVRI) Innovative Drug Development Initiative (IDDI) as an open debate platform for academia, the pharmaceutical industry and regulatory experts surrounding the future de...
Autores principales: | Nikkho, Sylvia, Fernandes, Peter, White, R. James, Deng, Chunqin (CQ), Farber, Harrison W., Corris, Paul A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682228/ https://www.ncbi.nlm.nih.gov/pubmed/33282181 http://dx.doi.org/10.1177/2045894020941491 |
Ejemplares similares
-
Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020) -
The Innovative Drug Development Initiative (IDDI) of the Pulmonary Vascular Research Institute (PVRI): A series of four guidance documents for academics, drug regulators and industry partners
por: Corris, Paul A, et al.
Publicado: (2020) -
Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
por: Nathan, Steven D., et al.
Publicado: (2022) -
Statement on imaging and pulmonary hypertension from the Pulmonary
Vascular Research Institute (PVRI)
por: Kiely, David G., et al.
Publicado: (2019) -
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
por: Blagden, Sarah P., et al.
Publicado: (2020)